Welcome to our dedicated page for Azitra SEC filings (Ticker: AZTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Azitra Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on precision dermatology. Recent disclosures cover proxy materials for annual and special stockholder meetings, shareholder voting procedures, board and governance matters, and meeting-status updates filed on Form 8-K.
Azitra's SEC reports also describe material agreements and capital-structure changes, including private placement securities, Series A preferred stock and Series B and Series C warrants. Other filings address furnished financial results, pipeline business updates, use of financing proceeds for research and development and working capital, and NYSE American continued-listing compliance matters tied to stockholders' equity standards.
Azitra, Inc. received a notice from NYSE American that it no longer meets the exchange’s listing standard requiring at least $4.0 million in stockholders’ equity for companies with losses in three of the four most recent fiscal years. As of June 30, 2025, Azitra reported stockholders’ equity of $2.2 million and losses in three of its four most recent fiscal years ended December 31, 2024.
The company has until October 31, 2025 to submit a plan to regain compliance by April 1, 2027. If the plan is accepted, Azitra will undergo periodic reviews, and failure to execute or regain compliance by that date may lead to delisting proceedings. The letter does not immediately affect the listing or trading of Azitra’s common stock and does not change its SEC reporting obligations.
Azitra Inc. states two offering scenarios and how net proceeds would fund operations under its current plan. If the company receives $8.95 million of net proceeds (based on gross proceeds of $10.0 million), management believes those proceeds, together with existing cash on hand, will satisfy its capital needs until October 2026. If the company receives $6.95 million of net proceeds (based on gross proceeds of $8.0 million), management believes those proceeds, without additional cash on hand, will satisfy its capital needs until September 2026. The filing discloses a historical net tangible book value per share as of June 30, 2025 of $0.48 and shows a pro forma net tangible book value per share increasing to $0.74 in one scenario and to $0.84 in another, with an indicated dilution of $0.14 per share to new investors.
Azitra, Inc. entered into a Modification Agreement with Alumni Capital LP that updates pricing terms under an existing equity purchase agreement for up to $20 million of common stock. The company can require Alumni Capital to buy shares in tranches of up to $750,000 each, or up to $4 million per purchase if both parties agree in writing. For each purchase, Azitra may choose between two pricing methods: either 90% of the lowest daily volume-weighted average price over a period of up to five business days after a purchase notice, or 97% of the lowest traded price from the date the purchase notice is delivered through the time Alumni Capital is ready to close. All other terms of the original April 24, 2025 purchase agreement remain in effect.
Alumni Capital LP, its general partner Alumni Capital GP LLC, and control person Ashkan Mapar filed a Schedule 13G reporting a deemed beneficial ownership of 2,605,586 shares of Azitra, Inc. common stock, representing 9.99% of the class. The reported position reflects shares the Fund may acquire under a Purchase Agreement and existing or to-be-issued Commitment Warrants, including a present right to acquire 849,700 shares on exercise of outstanding warrants. Ownership is subject to stated limits: a Warrant Ownership Limitation that caps ownership at 9.99% and a Purchase Agreement Ownership Limitation that currently caps purchases at 4.99% unless increased to 9.99% per the agreement.
Azitra, Inc. filed a Form 8-K reporting a corporate charter change: a Certificate of Amendment was filed with the Delaware Secretary of State on August 20, 2025. The 8-K includes standard filing checkboxes but provides no further detail about the amendment's text, purpose, or effect on capital structure, governance, equity classes, or shareholder rights. No financial tables, earnings data, or transaction details are included in the disclosed excerpt.
L1 Capital Global Opportunities Master Fund, Ltd. filed an amended Schedule 13G reporting beneficial ownership of 1,521,492 shares of Azitra, Inc. Class A common stock, representing 6.48% of the outstanding common shares. The filing states these shares represent common stock underlying 1,521,492 warrants purchased July 24, 2024, and the percentage is calculated using 23,476,354 shares outstanding as of August 11, 2025.
The reporting person is organized in the Cayman Islands and discloses sole voting and dispositive power over the 1,521,492 shares. Directors David Feldman and Joel Arber are identified as directors of the reporting fund; the filing includes customary disclaimers about their beneficial ownership limited to pecuniary interests. The amendment emphasizes the holdings were not acquired to influence control of the issuer.
Azitra, Inc. filed a current report to note that it released its financial results for the quarter ended June 30, 2025. On August 11, 2025, the company issued a press release describing these quarterly results, which is included as Exhibit 99.1 to the report and incorporated by reference. The filing clarifies that this earnings information is being furnished under the securities laws rather than formally filed, which affects how it is treated for liability purposes and future incorporation into other regulatory documents.
Azitra, Inc. filed a current report to note that it released its financial results for the quarter ended June 30, 2025. On August 11, 2025, the company issued a press release describing these quarterly results, which is included as Exhibit 99.1 to the report and incorporated by reference. The filing clarifies that this earnings information is being furnished under the securities laws rather than formally filed, which affects how it is treated for liability purposes and future incorporation into other regulatory documents.
Azitra, Inc. reported continuing pre‑commercial operations and clinical progress while facing significant financing pressure. For the six months ended June 30, 2025 the company recorded a net loss of $5.96 million, used $5.89 million of cash in operating activities and ended the period with $1.05 million of cash. Total assets declined to $3.96 million from $7.36 million at year-end 2024, and working capital was approximately $0.3 million, contributing to management's conclusion of substantial doubt about the company's ability to continue as a going concern.
The company advanced its development programs: ATR-12 dosed its first patient in August 2024 with initial safety results reported in H1 2025; ATR-04 received IND clearance and Fast Track designation and is expected to dose its first patient in Q3 2025; ATR-01 remains in lead optimization with an IND targeted for 2026. On April 24, 2025 Azitra established a $20 million equity line of credit (ELOC) with Alumni Capital, issued shares and warrants under the ELOC and reported gross proceeds of $1.7 million, with $18.3 million available under the facility as of August 11, 2025.
Azitra, Inc. reported continuing pre‑commercial operations and clinical progress while facing significant financing pressure. For the six months ended June 30, 2025 the company recorded a net loss of $5.96 million, used $5.89 million of cash in operating activities and ended the period with $1.05 million of cash. Total assets declined to $3.96 million from $7.36 million at year-end 2024, and working capital was approximately $0.3 million, contributing to management's conclusion of substantial doubt about the company's ability to continue as a going concern.
The company advanced its development programs: ATR-12 dosed its first patient in August 2024 with initial safety results reported in H1 2025; ATR-04 received IND clearance and Fast Track designation and is expected to dose its first patient in Q3 2025; ATR-01 remains in lead optimization with an IND targeted for 2026. On April 24, 2025 Azitra established a $20 million equity line of credit (ELOC) with Alumni Capital, issued shares and warrants under the ELOC and reported gross proceeds of $1.7 million, with $18.3 million available under the facility as of August 11, 2025.
Azitra held its 2025 annual meeting on June 23, where stockholders voted on several key proposals. Three out of four proposals were concluded, while one remains pending:
- Board Elections: All four director nominees were successfully elected: Francisco D. Salva, Travis Whitfill, Barbara Ryan, and John Schroer, with each receiving over 1 million votes in favor
- Auditor Appointment: Stockholders ratified Grassi & Co., CPAs as the independent auditor for FY2025, with 8.37 million votes in favor
- Share Issuance: Approved issuance of >19.99% of outstanding common stock under purchase agreement with Alumni Capital LP, receiving 1.2 million favorable votes
- Pending Vote: Proposal to increase authorized common stock from 100M to 200M shares was adjourned to July 3, 2025, allowing additional time for stockholder voting
The company maintains its status as an emerging growth company and trades on NYSE American under symbol AZTR.